MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review

Jung Han Kim _, Hyeong Su Kim and Bum Jun Kim

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:75500-75508. https://doi.org/10.18632/oncotarget.20824

Metrics: PDF 1162 views  |   HTML 1984 views  |   ?  


Jung Han Kim1,*, Hyeong Su Kim1,* and Bum Jun Kim1,2

1Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea

2Department of Internal Medicine, National Army Capital Hospital, The Armed Forces Medical Command, Sungnam 13574, Republic of Korea

*These authors contributed equally to this work

Correspondence to:

Jung Han Kim, email: [email protected], [email protected]

Keywords: MET, MET inhibitor, non-small-cell lung cancer, meta-analysis

Received: July 18, 2017     Accepted: August 27, 2017     Published: September 11, 2017


The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or standard chemotherapy in patients with advanced or metastatic NSCLC. A systematic computerized search of the electronic databases was carried out. From seven studies, 2,577 patients were included in the meta-analysis. Compared with patients in the placebo group, patients who received an additional MET inhibitor did not show significantly improved progression-free survival (hazard ration (HR) = 0.92 [95% confidence interval (CI): 0.79–1.08], P = 0.33) and overall survival (HR = 1.0 [95% CI: 0.90–1.11], P = 0.97). In the subgroup analysis, patients with MET-high NSCLC tended to show longer survival when treated with an additional MET inhibitor than those in the placebo group (HR = 0.76, [95% CI: 0.58–1.01], P = 0.06). In conclusion, this meta-analysis indicates that the addition of a MET inhibitor to an EGFR TKI or chemotherapy has no survival benefit over placebo in patients with advanced or metastatic NSCLC. Although patients with MET-high tumor tended to show better survival, further studies to explore more specific biomarkers are warranted to identify ideal candidates for MET inhibitors in NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20824